Dermatology

The exact cause of vitiligo is unknown. However, certain things, such as genetics or environmental factors, may play a role. Vitiligo is primarily thought of as an autoimmune disorder that causes depigmentation or loss of skin color. Factors that may contribute to the development of vitiligo, including genetics, hormones, and certain environmental exposures. The disease...

Vitiligo generally causes white patches on the skin. However, the extent and location of symptoms can vary by the type of vitiligo present. Vitiligo is a skin condition that causes pale patches to appear on the skin. It can happen anywhere on the body, but it most commonly develops on the face, hands, and feet....

Vitiligo is a skin disorder that can be diagnosed and treated in different ways. Learn more about how vitiligo is diagnosed and treated. Vitiligo is a skin condition in which the immune system attacks the pigment-producing cells in the skin. It causes the skin to lose its color, creating pale patches of skin. Vitiligo can...

Vitiligo is a debilitating, chronic condition that is linked to various causes. As it progresses, vitiligo may cause other health complications. Vitiligo is a skin condition that causes the loss of pigment in certain areas of the body. It most commonly affects the skin on the hands, feet, and face, but it can also affect...

Currently, there is no cure for vitiligo. However, treatments are available to help manage symptoms and improve well-being. Vitiligo is a skin condition that causes the loss of melanin in the skin, resulting in poorly melanated or unmelanated patches that appear pale to white in color. It most commonly affects people with dark skin but...

Melanoma brain metastasis (MBM) is found in 30–40% of patients with advanced melanoma. While treatment options are accessible, MBM remains a challenge to treat effectively. Around 30-40% of patients with advanced melanoma present with melanoma brain metastases (MBM) at diagnosis, with a higher percentage of patients exhibiting MBM at the time of death in autopsy....

Patients with multiple comorbidities in addition to melanoma may be less likely to receive appropriate treatment than patients without comorbidities. Clinicians and health systems are encouraged to address these inequalities in melanoma treatment. Disparities in the treatment of patients with melanoma exist in the United States and can have a negative impact on patient outcomes....

Age-related disparities exist in patients with advanced melanoma regarding overall survival. One study addressed the limited data on the use of immune checkpoint inhibitors (ICIs) in different age groups and their effect on survival rates. Immune checkpoint inhibitors (ICIs) changed the landscape of melanoma treatment, improving the overall survival (OS) of affected patients. Studies have...

Detecting melanoma early in patients is crucial for ensuring positive outcomes. A cross-sectional audit study explains the importance of increasing healthcare access and educating primary care physicians on diagnostic techniques. Melanoma is one of the most common cancers with a generally good prognosis if caught early. However, the late detection of melanoma could lead to...